Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

New seizure drug tested in kids: could it be a better option?

NCT ID NCT07163572

Disease control Sponsor: Muhammad Aamir Latif Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed This study
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 26, 2026 · Last updated Jun 26, 2026

Summary

This completed study compared two intravenous seizure medications, brivaracetam and levetiracetam, in 152 children aged 1 month to 16 years with status epilepticus (a prolonged seizure emergency). The goal was to see which drug stopped seizures faster within 30 minutes. Researchers also tracked side effects. The results may help doctors choose the best treatment for children in this critical situation.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
brivaracetam and levetiracetam (intravenous seizure medications)
What this could lead to
If brivaracetam works as well or better than levetiracetam, it could give doctors another option to quickly stop prolonged seizures in children.
What could go wrong
This is a single-center study with 152 children, so results may not apply to all kids. The trial only looked at stopping seizures within 30 minutes, not long-term outcomes.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Not a phased trial

Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.

Participants

152 people

The number who actually took part.

Started

Jan 2025

Finished

Aug 2025

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

1 month to 16 years

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Either gender * Aged one month to 16 years * Presenting with status epilepticus Exclusion Criteria: * Previously received intravenous antiseizure medication for the current episode prior to presentation * Known hypersensitivity to study drugs * Hemodynamically unstable, requiring inotropic support before administration

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Status epilepticus are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

Status Epilepticus

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Status epilepticus

Contacts and locations

Locations

  • The Children's Hospital and Institute of Child Health

    Multan, Punjab Province, 66000, Pakistan

More trials for these conditions

Other studies related to the condition(s) this trial covers.